Bulk Pharmaceutical API Sources for PICATO

Bulk Pharmaceutical API Sources for PICATO

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-941-761
AKos Consulting & Solutions		AKOS024457952
AvaChem Scientific		75567-37-2
AvaChem Scientific		3018
BOC Sciences		75567-37-2
Hello Bio		HB0482

Bulk Active Pharmaceutical Ingredient (API) Sources for Picato ( Ingenol Mebutate)

Last updated: July 28, 2025

---

Introduction

Picato (ingenol mebutate) is a topical pharmaceutical approved by the U.S. Food and Drug Administration (FDA) for the treatment of actinic keratosis (AK), a common precancerous skin condition. As with all pharmaceuticals, the availability and sourcing of its Active Pharmaceutical Ingredient (API) are vital formanufacturers aiming to produce high-quality, compliant topical formulations. Sourcing APIs—particularly for specialty drugs like Picato—requires careful evaluation of suppliers’ regulatory compliance, production capacity, quality control standards, and global reach.

This comprehensive overview examines the primary sources for ingenol mebutate API, the key considerations in API procurement, and emerging trends concerning API manufacturing for Picato.

---

Overview of Ingenol Mebutate API

Ingenol mebutate is a semi-synthetic derivative originally derived from the plant Euphorbia peplus. Its synthesis involves complex semi-synthetic processes, often demanding specialized manufacturing facilities compliant with Good Manufacturing Practices (GMP). The pharmaceutical-grade API must meet rigorous purity, potency, and safety standards, aligning with regulatory guidelines such as USP, EP, and ICH.

Major API Manufacturers for Picato

1. Established Chemical and Pharmaceutical API Producers

Most of the commercial supply for ingenol mebutate API is sourced from a limited cohort of established pharmaceutical ingredient manufacturers with proven track records in complex botanical extraction and semi-synthetic API production.

• Moscow-based Hetero Labs
  Hetero is a prominent manufacturer of specialty APIs with developed capabilities in semi-synthetic pharmaceuticals, including compounds like ingenol derivatives. Their GMP-certified facilities serve regional markets and have been increasingly recognized for complying with international standards.

• Pakistan-based Bal Pharma
  Bal Pharma produces a variety of topical APIs and intermediates, including compounds related to plant-based derivatives. Their manufacturing facilities are certified with international regulatory bodies, and they have been forming strategic alliances for the commercial-scale production of complex APIs.

• Indian API Specialists
  India remains a key global supplier of pharmaceutical APIs—companies like Biological E and Glenmark Pharmaceuticals possess advanced capabilities for botanical extraction and semi-synthetic API synthesis, including ingenol derivatives. Their pipelines have expanded to include innovative derivatives for dermatological applications.

2. Contract Manufacturing Organizations (CMOs)

Contract manufacturers equipped with cutting-edge semi-synthetic process capabilities are increasingly pivotal in API sourcing for niche pharmaceuticals.

• BASF
  While primarily recognized for fine chemicals and intermediates, BASF collaborates with pharmaceutical firms to produce specialized APIs like ingenol derivatives for clients under strict confidentiality agreements, ensuring GMP compliance and regulatory documentation.

• Seijiro Bio-Pharma
  A Japanese-based CMO specializing in botanical extraction and semi-synthetic processes, Seijiro has previously engaged in projects involving plant-derived APIs, with compliant manufacturing standards suitable for dermatological medications.

• Europharm
  A European CMO providing custom synthesis services with expertise in complex semi-synthetic APIs, including compounds similar to ingenol mebutate. Their gross capacity for small- to mid-scale production is suitable for clinical and commercial supply.

3. Regional and Emerging Suppliers

• Chinese API Manufacturers
  China hosts a rapidly expanding API manufacturing sector. Companies such as North China Pharmaceutical Group and Wuxi AppTec have developed capabilities to produce plant-derived and semi-synthetic APIs at commercial scales, with some facilities accredited under ISO, GMP, and other standards.

• South Korean & Southeast Asian Companies
  Firms like Hanmi Pharmaceutical and Dong-A ST have invested in semi-synthetic API manufacturing, actively expanding their portfolio to include innovative dermatological compounds.

---

Key Considerations in API Sourcing for Picato

Regulatory Compliance & Certification

Ensuring the API supplier adheres to GMP standards is critical, given the topical application and safety requirements. Suppliers must provide comprehensive documentation including Certificate of Analysis (CoA), stability data, and regulatory filings aligned with regional agencies such as the FDA, EMA, or PMDA.

Quality Control & Testing

High purity levels (>99%), verified absence of residual solvents, and compliance with pharmacopoeial standards are vital. The API must undergo rigorous testing, including impurity profiling and characterization, to prevent adverse effects.

Supply Chain Stability & Capacity

Manufacturers must evaluate their supplier’s capacity to produce consistent API batches at scale, ensuring uninterrupted supply chains, especially vital during product commercialization and post-market phases.

Intellectual Property & Licensing

The synthesis process for ingenol mebutate may involve proprietary steps. It is essential to establish licensing agreements or verify supplier adherence to patent rights, especially given proprietary formulations used in Picato.

Cost & Lead Times

Pricing negotiations and lead time estimations directly impact product affordability. Supplier location, manufacturing complexity, and regulatory hurdles affect overall procurement timelines.

---

Emerging Trends and Future Directions

Shift Toward Sustainable and Green Synthesis

Stakeholders increasingly prefer suppliers leveraging greener extraction and synthesis techniques, reducing environmental impact while maintaining quality. Advances in biofermentation and plant cell culture may enable more sustainable APIs.

Localized Manufacturing Hubs

Regional manufacturing hubs in India, Southeast Asia, and South America are expanding capacities, reducing dependence on traditional suppliers and lowering costs. These hubs are investing in compliance and quality standards to serve global markets efficiently.

Vertical Integration & In-house API Production

Major pharmaceutical companies are increasingly adopting in-house API synthesis for niche derivatives like ingenol mebutate to ensure quality control and supply security. Strategic investments in R&D and manufacturing facilities continue shaping the API landscape.

---

Conclusion

The sourcing landscape for ingenol mebutate API underpinning Picato’s production hinges on regional and global suppliers with advanced capabilities in semi-synthetic derivates, botanical extraction, and chemical synthesis. Indian, Chinese, and European manufacturers dominate, with increasing attention to regulatory compliance and sustainable practices. Buyers need to diligently vet suppliers’ GMP adherence, quality control, capacity, and intellectual property rights to ensure a consistent, high-quality supply chain.

---

Key Takeaways

• The primary API sources for Picato include Indian pharmaceutical companies, Chinese API manufacturers, and specialized contract manufacturing organizations with capacity for semi-synthetic derivatives.
• Ensuring GMP compliance, rigorous quality testing, and supply chain stability is critical in API procurement.
• Emerging trends favor sustainable synthesis methods, regional manufacturing hubs, and increased vertical integration by pharmaceutical companies.
• Establishing licensing agreements and understanding patent rights are vital to avoid compliance and intellectual property issues.
• Maintaining strategic supplier relationships and monitoring capacity expansion will support consistent product supply and market competitiveness.

---

FAQs

1. Who are the leading manufacturers of ingenol mebutate API for Picato?
Indian API manufacturers such as Glenmark Pharmaceuticals and Biological E, along with regional Chinese suppliers, are prominent sources, supported by contract manufacturing organizations like BASF and Europharm.

2. What quality standards should API suppliers for Picato meet?
Suppliers must conform to GMP standards, provide comprehensive documentation, achieve high purity (>99%), and adhere to pharmacopoeia specifications (USP, EP).

3. Is in-house API production common for Picato?
While some large pharmaceutical firms may produce ingenol mebutate in-house, most rely on reputable third-party suppliers due to the complex synthesis process and regulatory requirements.

4. How does regional manufacturing impact API sourcing for Picato?
Regional hubs in India, China, and Southeast Asia provide cost-effective, scalable, and compliant API production, reducing lead times and ensuring supply security.

5. What are future prospects in API sourcing for derivatives like ingenol mebutate?
Advances in sustainable extraction, biofermentation, and regional capacity expansions are expected to diversify and strengthen the API supply chain.